Literature DB >> 23258520

Radiosurgical treatment for epilepsy associated with cavernomas.

Marc Lévêque1, Romain Carron, Fabrice Bartolomei, Jean Régis.   

Abstract

Cavernous malformations (CMs) are congenital vascular malformations of the brain, which often present with drug-resistant epilepsy. Microsurgical excision remains the preferred approach for cortical-subcortical epileptogenic CMs that are not located in functional cortex. For patients presenting with seizures arising from eloquent cortex surrounding the lesion, radiosurgery appears to be a suitable alternative. We evaluated the effectiveness of Gamma Knife (GK) surgery in the management of drug-resistant seizures associated with CMs in a retrospective multicenter study. Forty-nine patients with cortical or subcortical CMs with severe long-term drug-resistant epilepsy underwent radiosurgery. The mean duration of epilepsy before these GK procedures was 7.5 (±9.3) years. The mean frequency of seizures was 6.9/month (±14). The mean marginal radiation dose was 19.17 Gy. At the last follow-up examination, 53% were seizure free. A highly significant decrease in the number of seizures was achieved for another 20%. The remaining 26% of patients showed little or no improvement. The morbidity was low. Radiosurgery is a promising management modality for epilepsy associated with CMs. The determination of the extent of the epileptogenic zone in CMs and dose selection are the critical steps towards successful radiosurgical outcome. Further prospective work is necessary to validate our data.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 23258520     DOI: 10.1159/000341785

Source DB:  PubMed          Journal:  Prog Neurol Surg        ISSN: 0079-6492


  1 in total

1.  Evaluation of linear accelerator (LINAC)-based stereotactic radiosurgery (SRS) for cerebral cavernous malformations: a 15-year single-center experience.

Authors:  Omer Sager; Murat Beyzadeoglu; Ferrat Dincoglan; Bora Uysal; Hakan Gamsiz; Selcuk Demiral; Kaan Oysul; Bahar Dirican; Sait Sirin
Journal:  Ann Saudi Med       Date:  2014 Jan-Feb       Impact factor: 1.526

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.